Market Research Logo

Myelodysplastic Syndrome - Pipeline Review, H1 2015

Myelodysplastic Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Myelodysplastic Syndrome - Pipeline Review, H1 2015’, provides an overview of the Myelodysplastic Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Myelodysplastic Syndrome Overview
Therapeutics Development
Pipeline Products for Myelodysplastic Syndrome - Overview
Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis
Myelodysplastic Syndrome - Therapeutics under Development by Companies
Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes
Myelodysplastic Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Myelodysplastic Syndrome - Products under Development by Companies
Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc.
Acceleron Pharma, Inc.
Actinium Pharmaceuticals, Inc.
Advancell
Agios Pharmaceuticals, Inc.
Altor BioScience Corporation
Amgen Inc.
Apogenix GmbH
Aptose Biosciences Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co., Ltd.
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celator Pharmaceuticals, Inc.
Celgene Corporation
Celldex Therapeutics, Inc.
Cellerant Therapeutics, Inc.
Celyad
Clevexel Pharma SAS
Concert Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Cyclacel Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eleos Inc.
Eli Lilly and Company
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Fujifilm Corporation
Gamida Cell Ltd.
GlaxoSmithKline Plc
Incyte Corporation
Juno Therapeutics Inc.
JW Pharmaceutical Corporation
Kainos Medicine, Inc.
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kiadis Pharma B.V.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings, Inc.
medac GmbH
MedImmune, LLC
MEI Pharma, Inc.
Merck & Co., Inc.
Merus B.V.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mirna Therapeutics, Inc.
Novartis AG
Onconova Therapeutics, Inc.
Opsona Therapeutics Ltd.
OXiGENE, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Rich Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sunesis Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Limited
Threshold Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
Myelodysplastic Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cytarabine hydrochloride + daunorubicin hydrochloride) - Drug Profile
(decitabine + E-7727) - Drug Profile
4SC-202 - Drug Profile
acadesine - Drug Profile
AG-120 - Drug Profile
ALT-803 - Drug Profile
Antibody to Target Cancer Stem Cell for Cancer - Drug Profile
APG-101 - Drug Profile
APTO-253 - Drug Profile
ATIR-101 - Drug Profile
azacitidine - Drug Profile
BBMPI-03 - Drug Profile
BI-836858 - Drug Profile
binimetinib - Drug Profile
birinapant - Drug Profile
BL-8040 - Drug Profile
BLI-1301 - Drug Profile
bortezomib - Drug Profile
BP-100101 - Drug Profile
BR-05001 - Drug Profile
CC-90007 - Drug Profile
CDX-1401 - Drug Profile
Cell Therapy to Target CD174 for Oncology - Drug Profile
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile
Cell Therapy to Target WT1 for Cancer - Drug Profile
cenersen sodium - Drug Profile
CIGB-300 - Drug Profile
CMCS-1 - Drug Profile
CPI-0610 - Drug Profile
CPI-613 - Drug Profile
CSC-012 - Drug Profile
CTP-221 - Drug Profile
CVXL-0056 - Drug Profile
CWP-291 - Drug Profile
darbepoetin alfa (recombinant) - Drug Profile
dasatinib - Drug Profile
Dendritic Cell Therapy for Hematological Malignancies - Drug Profile
Dendritic Cell Therapy for Oncology - Drug Profile
Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile
Drug to Inhibit NR2F6 Protein for Leukemia - Drug Profile
DS-3032 - Drug Profile
DSP-7888 - Drug Profile
durvalumab - Drug Profile
E-6201 - Drug Profile
eltrombopag olamine - Drug Profile
entinostat - Drug Profile
epacadostat - Drug Profile
EPZ-5676 - Drug Profile
erismodegib - Drug Profile
everolimus - Drug Profile
evofosfamide - Drug Profile
FF-10501 - Drug Profile
galunisertib - Drug Profile
ganetespib - Drug Profile
glasdegib - Drug Profile
guadecitabine - Drug Profile
HDM-201 - Drug Profile
ilorasertib - Drug Profile
indisulam - Drug Profile
Iomab-B - Drug Profile
ixazomib citrate - Drug Profile
JTCR-016 - Drug Profile
KB-004 - Drug Profile
KHK-2823 - Drug Profile
KM-101 - Drug Profile
LB-100 - Drug Profile
lenalidomide - Drug Profile
lirilumab - Drug Profile
lurbinectedin - Drug Profile
luspatercept - Drug Profile
MCLA-­117 - Drug Profile
midostaurin - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibodies to Target CD16 and CD33 for Oncology - Drug Profile
Monoclonal Antibody Conjugate 2 to Target CD45 for Cancer - Drug Profile
Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS - Drug Profile
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile
MRX-102 - Drug Profile
MRX-34 - Drug Profile
napabucasin - Drug Profile
NiCord - Drug Profile
omacetaxine mepesuccinate - Drug Profile
ONC-201 - Drug Profile
OPN-305 - Drug Profile
OXi-4503 - Drug Profile
pacritinib - Drug Profile
pembrolizumab - Drug Profile
pevonedistat hydrochloride - Drug Profile
pexmetinib - Drug Profile
PIM-447 - Drug Profile
pracinostat - Drug Profile
quizartinib dihydrochloride - Drug Profile
rigosertib sodium - Drug Profile
RP-323 - Drug Profile
ruxolitinib phosphate - Drug Profile
S-055746 - Drug Profile
sapacitabine - Drug Profile
selinexor - Drug Profile
SL-401 - Drug Profile
Small Molecule to Inhibit KDM1A for AML, MDS and Sickle Cell Disease - Drug Profile
Small Molecules for Myelodysplastic Syndrome - Drug Profile
sotatercept - Drug Profile
StemEx - Drug Profile
temozolomide - Drug Profile
TEN-010 - Drug Profile
TG-02 - Drug Profile
tosedostat - Drug Profile
trametinib dimethyl sulfoxide - Drug Profile
treosulfan - Drug Profile
ulixertinib - Drug Profile
Vaccine for Oncology - Drug Profile
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Vaccine to Target WT1 for Oncology - Drug Profile
vismodegib - Drug Profile
volasertib - Drug Profile
vorinostat - Drug Profile
vosaroxin - Drug Profile
WT-4869 - Drug Profile
Myelodysplastic Syndrome - Recent Pipeline Updates
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H1 2015
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2015
Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2015
Myelodysplastic Syndrome - Pipeline by AbbVie Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Advancell, H1 2015
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corporation, H1 2015
Myelodysplastic Syndrome - Pipeline by Amgen Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H1 2015
Myelodysplastic Syndrome - Pipeline by Aptose Biosciences Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by BioLineRx, Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Myelodysplastic Syndrome - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Boston Biomedical, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2015
Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H1 2015
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Celyad, H1 2015
Myelodysplastic Syndrome - Pipeline by Clevexel Pharma SAS, H1 2015
Myelodysplastic Syndrome - Pipeline by Concert Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp., H1 2015
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Eleos Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H1 2015
Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H1 2015
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2015
Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H1 2015
Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H1 2015
Myelodysplastic Syndrome - Pipeline by Kainos Medicine, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H1 2015
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H1 2015
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by medac GmbH, H1 2015
Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H1 2015
Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Merus B.V., H1 2015
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Novartis AG, H1 2015
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Pharma Mar, S.A., H1 2015
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H1 2015
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
Myelodysplastic Syndrome - Dormant Projects, H1 2015
Myelodysplastic Syndrome - Dormant Projects (Contd..1), H1 2015
Myelodysplastic Syndrome - Dormant Projects (Contd..2), H1 2015
Myelodysplastic Syndrome - Dormant Projects (Contd..3), H1 2015
Myelodysplastic Syndrome - Discontinued Products, H1 2015
Myelodysplastic Syndrome - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H1 2015
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report